Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of inhaled interferon alfa-1b for pediatric RSV lower respiratory tract infection
CTR20240731Phase 3Active
- Sponsor
- Kexing Biopharm
- Start
- Mar 2024
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in respiratory syncytial virus disease (RSV), bronchiolitis and pneumonia comparing human interferon alfa-1b inhalation solution with placebo inhalation solution (2 arms). Started Mar 2024; status: active.
02
Drugs
recombinant human interferon alpha-1b
03
Conditions
respiratory syncytial virus disease (RSV)bronchiolitispneumonia
Beyond the preview
Go deeper on CTR20240731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240731.